157 related articles for article (PubMed ID: 34303837)
1. How good are mast cell mediators?
Weiler CR
Ann Allergy Asthma Immunol; 2021 Oct; 127(4):410-411. PubMed ID: 34303837
[No Abstract] [Full Text] [Related]
2. Mast Cell Mediators of Significance in Clinical Practice in Mastocytosis.
Butterfield JH; Ravi A; Pongdee T
Immunol Allergy Clin North Am; 2018 Aug; 38(3):397-410. PubMed ID: 30007459
[TBL] [Abstract][Full Text] [Related]
3. Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation.
Butterfield JH
Int Arch Allergy Immunol; 2020; 181(1):43-50. PubMed ID: 31722348
[TBL] [Abstract][Full Text] [Related]
4. Increased leukotriene E4 excretion in systemic mastocytosis.
Butterfield JH
Prostaglandins Other Lipid Mediat; 2010 Jun; 92(1-4):73-6. PubMed ID: 20380889
[TBL] [Abstract][Full Text] [Related]
5. Hereditary alpha tryptasemia in identical twins.
Bethea LH; Tuano KS; Seth N; Chinen J
Ann Allergy Asthma Immunol; 2021 Oct; 127(4):503-504. PubMed ID: 34157394
[No Abstract] [Full Text] [Related]
6. Assessing anaphylactic risk? Consider mast cell clonality.
Metcalfe DD; Schwartz LB
J Allergy Clin Immunol; 2009 Mar; 123(3):687-8. PubMed ID: 19281912
[No Abstract] [Full Text] [Related]
7. Determination of plasma heparin level improves identification of systemic mast cell activation disease.
Vysniauskaite M; Hertfelder HJ; Oldenburg J; Dreßen P; Brettner S; Homann J; Molderings GJ
PLoS One; 2015; 10(4):e0124912. PubMed ID: 25909362
[TBL] [Abstract][Full Text] [Related]
8. Urinary mediators and asthma.
Dworski R; Sheller JR
Clin Exp Allergy; 1998 Nov; 28(11):1309-12. PubMed ID: 9824399
[No Abstract] [Full Text] [Related]
9. Nontryptase Urinary and Hematologic Biomarkers of Mast Cell Expansion and Mast Cell Activation: Status 2022.
Butterfield JH
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1974-1984. PubMed ID: 35346887
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers in the diagnosis of anaphylaxis: making nature disclose her mysteries.
Levy JH
Clin Exp Allergy; 2009 Jan; 39(1):5-7. PubMed ID: 19032357
[No Abstract] [Full Text] [Related]
11. Mast cell disorders: A framework of allergy and hematology symptoms leading to personalized treatments.
Castells MC
Ann Allergy Asthma Immunol; 2021 Oct; 127(4):403-404. PubMed ID: 34593102
[No Abstract] [Full Text] [Related]
12. New Insights into Clonal Mast Cell Disorders Including Mastocytosis.
Volertas S; Schuler CF; Akin C
Immunol Allergy Clin North Am; 2018 Aug; 38(3):341-350. PubMed ID: 30007455
[TBL] [Abstract][Full Text] [Related]
13. Pathology of extramedullary mastocytosis.
Doyle LA; Hornick JL
Immunol Allergy Clin North Am; 2014 May; 34(2):323-39. PubMed ID: 24745677
[TBL] [Abstract][Full Text] [Related]
14. The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome.
Butterfield J; Weiler CR
J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2533-2541. PubMed ID: 32142966
[TBL] [Abstract][Full Text] [Related]
15. Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence.
Hamilton MJ
Immunol Allergy Clin North Am; 2018 Aug; 38(3):469-481. PubMed ID: 30007464
[TBL] [Abstract][Full Text] [Related]
16. [Leukotriene (B4, C4, D4, E4)].
Kitamura S
Nihon Rinsho; 2005 Aug; 63 Suppl 8():28-33. PubMed ID: 16149443
[No Abstract] [Full Text] [Related]
17. Mast cell disorders: Protean manifestations and treatment responses.
Chen M; Kim A; Zuraw B; Doherty TA; Christiansen S
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):128-130. PubMed ID: 29604336
[No Abstract] [Full Text] [Related]
18. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis.
Ono E; Taniguchi M; Mita H; Fukutomi Y; Higashi N; Miyazaki E; Kumamoto T; Akiyama K
Clin Exp Allergy; 2009 Jan; 39(1):72-80. PubMed ID: 19128354
[TBL] [Abstract][Full Text] [Related]
19. Symptoms of mast cell activation: The patient perspective.
Jennings SV; Slee VM; Finnerty CC; Hempstead JB; Bowman AS
Ann Allergy Asthma Immunol; 2021 Oct; 127(4):407-409. PubMed ID: 34271184
[No Abstract] [Full Text] [Related]
20. Response to cyclosporin and low-dose methylprednisolone in aggressive systemic mastocytosis.
Kurosawa M; Amano H; Kanbe N; Igarashi Y; Nagata H; Yamashita T; Kurimoto F; Miyachi Y
J Allergy Clin Immunol; 1999 May; 103(5 Pt 2):S412-20. PubMed ID: 10329843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
